Alkem Laboratories Limited (ALKEM.NS) fair value

ACCE thesis

Alkem Laboratories makes generic and specialty branded formulations for India's domestic chronic-therapy market and for export, with a sizeable US and emerging-market generics business alongside its Indian brand franchise. The Indian branded business gives it pricing power and recurring prescription volume that most generic peers lack, and the 64.8% gross margin reflects that mix. Revenue grew 10.9% over the reported period, while the stock trades at 27.8 times trailing earnings and 22.4 times forward earnings, so the market is pricing in earnings growth well ahead of the top line. The forward multiple sits about five turns below the trailing one, which means consensus expects a meaningful step-up in profit, and whether that materialises is the question a deeper look would need to answer. With an 17.8% operating margin and no index membership at ACCE's screen, the name is worth a closer read on margin trajectory and US pipeline timing before any position is considered.